Denali Therapeutics ^{Priced, Nasdaq: DNLI}

Our goal is to discover and develop therapeutics to defeat degeneration. We have a focused yet diversified portfolio that currently consists of six core and five seed programs. Our most advanced program targets LRRK2 for the treatment of Parkinson's disease and has a product candidate currently in Phase 1 development. Our next most advanced program targets RIPK1 for the treatment of Alzheimer's disease and ALS and current has a product candidate in IND-enabling studies with an IND or CTA filing planned for early 2018. In addition, we have four core programs in preclinical development that use our proprietary blood-brain barrier (BBB) platform technology.